

CORONAVIRUS

Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening

Daniel B. Larremore^{1,2,*}, Bryan Wilder³, Evan Lester^{4,5}, Soraya Shehata^{5,6}, James M. Burke⁴, James A. Hay^{7,8}, Milind Tambe³, Michael J. Mina^{7,8,9,*†}, Roy Parker^{2,4,6,10,*†}

The COVID-19 pandemic has created a public health crisis. Because SARS-CoV-2 can spread from individuals with presymptomatic, symptomatic, and asymptomatic infections, the reopening of societies and the control of virus spread will be facilitated by robust population screening, for which virus testing will often be central. After infection, individuals undergo a period of incubation during which viral titers are too low to detect, followed by exponential viral growth, leading to peak viral load and infectiousness and ending with declining titers and clearance. Given the pattern of viral load kinetics, we model the effectiveness of repeated population screening considering test sensitivities, frequency, and sample-to-answer reporting time. These results demonstrate that effective screening depends largely on frequency of testing and speed of reporting and is only marginally improved by high test sensitivity. We therefore conclude that screening should prioritize accessibility, frequency, and sample-to-answer time; analytical limits of detection should be secondary.

INTRODUCTION

Successful population screening testing of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) depends on understanding both the dynamics of spread between individuals and the dynamics of the virus within the human body. Critically, the ability of SARS-CoV-2 to spread from individuals who are presymptomatic, symptomatic, or essentially asymptomatic (1–3) means that diagnosis and isolation based on symptoms alone will be unable to prevent ongoing spread (4, 5). As a consequence, the use of population screening testing to identify infectious individuals presents one possible means to break enough transmission chains to suppress the ongoing pandemic and reopen societies, with or without a vaccine.

The reliance on testing as a means to safely reopen societies has placed a microscope on the analytical sensitivity of virus assays, with a gold standard of quantitative real-time polymerase chain reaction (RT-qPCR). These assays have analytical limits of detection that are usually within around 10^3 viral RNA copies per milliliter (cp/ml) (6). However, RT-qPCR remains expensive and, as a laboratory-based assay, often has sample-to-result times of 24 to 48 hours. New developments in SARS-CoV-2 diagnostics have the potential to reduce cost substantially, allowing for expanded testing or greater frequency of testing and can reduce turnaround time to minutes (7–9). These assays, however, largely do not meet the gold standard for analytical sensitivity, which has encumbered the widespread use of these assays (10).

¹Department of Computer Science, University of Colorado Boulder. ²BioFrontiers Institute, University of Colorado Boulder. ³Center for Research on Computation and Society, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University. ⁴Department of Biochemistry, University of Colorado Boulder. ⁵Medical Scientist Training Program, University of Colorado Anschutz Medical Campus. ⁶Department of Molecular, Cellular and Developmental Biology, University of Colorado Boulder. ⁷Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health. ⁸Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health. ⁹Department of Pathology, Brigham and Women's Hospital, Harvard Medical School. ¹⁰Howard Hughes Medical Institute.

*Corresponding author. Email: daniel.larremore@colorado.edu (D.B.L.); mmina@hsph.harvard.edu (M.J.M.); roy.parker@colorado.edu (R.P.)

†These authors contributed equally to this work.

Three features of the viral increase, infectivity, and decline during SARS-CoV-2 infection led us to hypothesize that there might be minimal differences in effective screening regimens using viral detection tests of different sensitivities, such as RT-qPCR with a limit of detection (LOD) at 10^3 cp/ml (6) compared to often cheaper or faster assays with higher LODs [i.e., around 10^5 cp/ml (7–9)] such as point-of-care nucleic acid loop-mediated isothermal amplification (LAMP) and rapid antigen tests (Fig. 1A).

First, since filtered samples collected from patients displaying less than 10^6 N or E RNA cp/ml contain minimal or no measurable infectious virus (11–13), either class of test should detect individuals who are currently infectious. The absence of infectious particles at viral RNA concentrations $<10^6$ cp/ml is likely due to (i) the fact that the nucleocapsid and envelope RNAs are also present in abundant subgenomic mRNAs, leading to overestimation of the number of actual viral genomes by ~ 100 to $1000\times$ (14); (ii) technical artifacts of RT-PCR at Ct values >35 due to limited template (15, 16); and (iii) the production of noninfectious viral particles as is commonly seen with a variety of RNA viruses (17). Second, during the exponential growth of the virus, the time difference between 10^3 and 10^5 cp/ml is short, allowing only a limited window in which only the more sensitive test could diagnose individuals. For qPCR, this corresponds to the time required during viral growth to go from Ct values of 40 to ~ 34 . While this time window for SARS-CoV-2 is not yet rigorously defined (18), for other respiratory viruses such as influenza, and in ferret models of SARS-CoV-2 transmission, it is on the order of a day (19, 20). Last, high-sensitivity screening tests, when applied during the viral decline accompanying recovery, are unlikely to substantially affect transmission because such individuals detected have low, if any, infectiousness (14). A recent review by Cevik *et al.* (18) notes that no study to date has successfully cultured live virus more than 9 days after the onset of symptoms.

RESULTS

Impact of repeated population screening on individuals

To examine how repeated population screening would reduce the average infectiousness of individuals, we first modeled the viral loads and infectiousness curves of 10,000 simulated individuals using the

Copyright © 2021
The Authors, some
rights reserved;
exclusive licensee
American Association
for the Advancement
of Science. No claim to
original U.S. Government
Works. Distributed
under a Creative
Commons Attribution
NonCommercial
License 4.0 (CC BY-NC).




Fig. 1. Population screening regimen effectiveness depends on frequency. (A) An example viral load trajectory is shown with LOD thresholds of two tests and a hypothetical positive test on day 6, 2 days after peak viral load. Twenty other stochastically generated viral loads are shown to highlight trajectory diversity (light gray; see Materials and Methods). dx, diagnosis. (B) Relative infectiousness for the viral load shown in (A) before test, totaling 35% (blue), and post-isolation, totaling 65% (black). (C) Screening programs using tests at LODs of 10^3 and 10^5 at frequencies indicated were applied to 10,000 individuals' trajectories of whom 35% would undergo symptomatic isolation near their peak viral load if they had not been tested and isolated first. Total infectiousness removed during screening (colors) and self-isolation (hatch) are shown for repeated population screening as indicated, relative to total infectiousness with no screening or self-isolation. (D) The impact of repeated population screening on the infectiousness of 100 individuals is shown for each screening regimen and no testing, as indicated, with each individual colored by test if their infection was detected during infectiousness (medians, black lines) or colored blue if their infection was missed by screening or detected positive after their infectious period (medians, blue lines). Units are arbitrary and scaled to the maximum infectiousness of sampled individuals.

predicted viral trajectories of SARS-CoV-2 infections based on key features of latency, growth, peak, and decline identified in the literature (Fig. 1A; see Materials and Methods). Accounting for these within-host viral kinetics, we calculated what percentage of their total infectiousness would be removed by screening and isolation (Fig. 1B) with tests at LOD of 10^3 and 10^5 and at different testing frequencies. Here, infectiousness was taken to be proportional to the logarithm of viral load in excess of 10^6 cp/ml (with alternative assumptions addressed in sensitivity analyses; see the Supplementary Materials), consistent with the observation that presymptomatic patients are most infectious just before the onset of symptoms (21) and evidence that the efficiency of viral transmission coincides with peak viral loads, which was also identified during the related 2003 SARS outbreak (22, 23). We considered that 35% of patients would undergo symptomatic isolation within 3 days of their peak viral load if they had not been tested and isolated first, and 65% would have sufficiently mild or no symptoms such that they would not isolate unless they were detected by testing. On the basis of recent results, we modeled asymptomatic and symptomatic infections as having the same initial viral loads (1, 24–26) but with faster clearance among asymptomatics (see Materials and Methods) (24, 26–29).

This analysis demonstrated that there was little difference in averting infectiousness between the two classes of test. Marked reductions in total infectiousness of the individuals were observed by testing daily or every third day, 62 to 66% reduction when testing weekly, and 45 to 47% under biweekly testing (Fig. 1C). Because viral loads and infectiousness vary across individuals, we also analyzed the impact of different screening regimens on the distribution of individuals' infectiousness, revealing that more sporadic testing

leads to an increased likelihood that individuals will test positive after they are no longer infectious or be missed by testing entirely (Fig. 1D).

Impact of repeated screening on a population

Above, we assumed that each infection was independent. To investigate the effects of population screening strategies at the population level, we used simulations to monitor whether epidemics were contained or became uncontrolled while varying the frequencies at which the test was administered, ranging from daily testing to testing every 14 days, and considering tests with LOD of 10^3 and 10^5 , analogous to RT-qPCR and RT-LAMP/rapid antigen tests, respectively. We integrated individual viral load trajectories into two different epidemiological models to ensure that important observations were independent of the specific modeling approach. The first model is a simple fully mixed model representing a population of 20,000, similar to a large university setting, with a constant rate of external infection approximately equal to one new import per day. The second model is a previously described agent-based model with both within-household and age-stratified contact structure based on census microdata in a city representative of New York City (30), which we initialized with 100 cases without additional external infections. Individual viral loads were simulated for each infection, and individuals who received a positive test result were isolated, but contact tracing and monitoring were not included to more conservatively estimate the impacts of screening alone (31, 32). Model details and parameters are fully described in Materials and Methods.

We observed that a population screening regimen administering either test with high-frequency limited viral spread, measured by

both a reduction in the reproductive number R (Fig. 2, A and B; see Materials and Methods for calculation procedure) and the total infections that persisted despite different screening programs, expressed relative to no screening (Fig. 2, C and D). Testing frequency was found to be the primary driver of population-level epidemic control, with only a small margin of improvement provided by using a more sensitive test. Direct examination of simulations showed that with no testing or biweekly testing, infections were uncontrolled, whereas screening weekly with either $\text{LOD} = 10^3$ or 10^5 effectively attenuated surges of infections (examples are shown in Fig. 3).

The relationship between test sensitivity and the frequency of testing required to control outbreaks in both the fully mixed model and the agent-based model generalize beyond the examples shown in Fig. 2 and are also seen at other testing frequencies, sensitivities, and asymptomatic fractions. We simulated both models at LODs of 10^3 , 10^5 , and 10^6 and for testing ranging from daily to every 14 days. For those, we measured each population screening policy's impact on total infections (fig. S1, A and B) and on R (fig. S1, C and D). In Fig. 2, we modeled infectiousness as proportional to \log_{10} of viral load. To address whether these findings are sensitive to this modeled relationship, we performed similar simulations with infectiousness proportional to viral load (fig. S2) or uniform above $10^6/\text{ml}$ (fig. S3). We found that results were robust to these large variations in the modeled relationship between infectiousness and viral load. To further address whether our results depended on the exact 35% fraction of individuals assumed to be behaviorally symptomatic, we performed sensitivity analyses with fewer (20%) or more (50%) symptomatic individuals and found no meaningful difference in results (fig. S4).

Impact of delayed test results

An important variable in testing is the time between a test's sample collection and the reporting of a diagnosis. To examine how time to reporting affected epidemic control, we reanalyzed both the reduc-

tion in individuals' infectiousness and the epidemiological simulations, comparing the results of instantaneous reporting (reflecting a rapid point-of-care assay), 1-day delay, and 2-day delay (Fig. 4, A and B). Delays in reporting markedly decreased the reduction in infectiousness in individuals as seen by the total infectiousness removed (Fig. 4C), the distribution of infectiousness in individuals (Fig. 4D), or the dynamics of the epidemiological models (Fig. 5). This result was robust to the modeled relationship between infectiousness and viral load in both simulation models and for various test sensitivities and frequencies (fig. S5). These results highlight that delays in reporting lead to markedly less effective control of viral spread and emphasize that fast reporting of results is critical in any screening regimen. These results also reinforce the relatively smaller benefits of improved LODs.

Generality of findings to changes in modeling assumptions

Communities vary in their transmission dynamics because of difference in rates of imported infections and in the basic reproductive number R_0 , both of which will influence the frequency and sensitivity with which screening tests must occur. We performed two analyses to illustrate this point. First, we varied the rate of external infection in our fully mixed model and confirmed that when the external rate of infection is higher, more frequent screening is required to prevent outbreaks (fig. S6A). Second, we varied the reproductive number R_0 between infected individuals in both models and confirmed that at higher R_0 , more frequent screening is also required (fig. S6, B and C). This may be relevant to institutions like college campuses or military bases wherein frequent classroom setting or dormitory living is likely to increase contact rates. Thus, the specific strategy for successful population screening will depend on the current community infection prevalence and transmission rate.

The generality of our findings to different epidemiological parameters (fig. S6), relationships between viral load and infectiousness




Fig. 2. Repeated population screening affects disease dynamics. Both the fully mixed compartmental model (top row) and agent-based model (bottom row) are affected by repeated population screening. (A and B) More frequent testing reduces the effective reproductive number R , shown as the percentage by which R_0 is reduced, $100 \times (R_0 - R)/R_0$. Values of R were estimated from 50 independent simulations of dynamics with 100% of the population participating (see Materials and Methods). (C and D) Relative to no testing (gray bars), screening suppresses the total number of infections in both models when testing every day or every 3 days but only partially mitigates total cases for weekly or biweekly testing. Error bars indicate inner 95% quantiles of 50 independent simulations each.




Fig. 3. Example simulation trajectories from fully mixed model with repeated population screening. Simulation trajectories show the number of infected individuals in a population of $N = 20,000$ with a constant rate of external infection set to $1/N$ per person per day, i.e., around one imported case per day, and full participation in the testing regimen. Infections are classified as freely mixing in the population (blue), isolated because of a positive test (black), or isolated because of symptoms (red) in four simulated example scenarios with $R_0 = 2.5$. (A) No screening. (B) Weekly testing at $LOD 10^3$. (C) Weekly testing at $LOD 10^5$. (D) Testing every 3 days with $LOD 10^5$. Note the variation in the vertical axis scales. The models are fully described in Materials and Methods.




Fig. 4. Effectiveness of screening is compromised by delays in reporting. (A) An example viral load trajectory is shown with LOD thresholds of two tests and a hypothetical positive test on day 6 but with results reported on day 8. Twenty other stochastically generated viral loads are shown to highlight trajectory diversity (light gray; see Materials and Methods). (B) Relative infectiousness for the viral load shown in (A) pretest (totaling 35%; blue) and posttest but before diagnosis (totaling 34%; green) and after isolation (totaling 31%; black). (C) Population screening programs using tests at $LODs$ of 10^3 and 10^5 at frequencies indicated and with results returned after 0, 1, or 2 days (indicated by small text beneath bars) were applied to 10,000 individuals' trajectories of whom 35% were symptomatic and self-isolated after peak viral load if they had not been tested and isolated first. Total infectiousness removed during screening (colors) and self-isolation (hatch) is shown, relative to total infectiousness with no screening or self-isolation. Delays substantially affect the fraction of infectiousness removed. (D) The impact of screening with delays in returning diagnosis of 0, 1, or 2 days (small text beneath the axis) on the infectiousness of 100 individuals is shown for each population screening regimen and no testing, as indicated, with each individual colored by test if their infection was detected during infectiousness (medians, black lines) or colored blue if their infection was missed by screening or diagnosed positive after their infectious period (medians, blue lines). Units are arbitrary and scaled to the maximum infectiousness of sampled individuals. a.u., arbitrary units.




Fig. 5. Delays in reporting decrease the epidemiological impact of testing-driven isolation. The effectiveness of population screening programs is markedly diminished by delays in reporting in both the fully mixed compartmental model (top row) and agent-based model (bottom row). (**A** and **B**) The impact of testing every day, 3 days, weekly, or biweekly on the reproductive number R , calculated as $100 \times (R_0 - R)/R_0$, is shown for LODs 10^3 and 10^5 and delays of 0, 1, or 2 days (small text below the axis). Values of R were estimated from 50 independent simulations of dynamics (see Materials and Methods). (**C** and **D**) Relative to no testing (gray bars), repeated population screening suppresses the total number of infections in both models when testing every day or every 3 days, but delayed results lead to only partial mitigation of total cases, even for testing every day or 3 days. Error bars indicate inner 95% quantiles of 50 independent simulations each.

(figs. S2 and S3), and proportion of symptomatic individuals (fig. S4) led us to ask whether a more general mathematical formula could predict R without requiring epidemiological simulation. We derived such a formula (text S1) and found that its predicted values of R were nearly perfectly correlated with simulation-estimated values (Pearson's $r = 0.998$, $P < 10^{-6}$; fig. S7), providing a mathematical alternative to simulation-based sensitivity analyses.

Repeated population screening to mitigate an ongoing epidemic

The impact of repeated population screening on transmission dynamics led us to hypothesize that testing could be used as an active tool to mitigate an ongoing epidemic. To test this idea, we simulated an outbreak situation using both the fully mixed and agent-based models but with three additional conditions. First, we assumed that in an ongoing pandemic, other mitigating interventions would cause the reproductive number to be lower although nevertheless larger than one. Second, we considered that not all individuals would want to or be able to participate in a SARS-CoV-2 screening program. Third, we assumed that the collection of samples for testing, if performed on a large scale, could result in imperfect sample collection, causing an increase in the false-negative rate, independent of an assay's analytical sensitivity. These modifications are fully described in Materials and Methods.

We simulated epidemics in which screening began only at the point when uncontrolled infections reached 4% prevalence. On the basis of results from our previous analyses, we considered a less sensitive but rapid test with LOD 10^5 cp/ml and a 0-day delay in results and further assumed that 10% of would-be positive samples would be negative because of improper sample collection. We then examined scenarios of testing every 3 days and every 7 days, with either 50 or 75% of individuals participating, starting from a partially mit-

igated $R_0 = 1.5$. We found that testing 75% of individuals every 3 days was sufficient to drive the epidemic toward extinction within 6 weeks and reduce cumulative incidence by 88% and that other combinations also had successful but less rapid mitigating impacts, particularly when compared with no intervention (Fig. 6). Notably, even weekly testing with 50% participation was able to reduce the peak and length of the outbreak, illustrating how even partial screening using a test with 100 \times lower molecular sensitivity than PCR can have public health benefits when used frequently (Fig. 6). Repeating these simulations using a test with LOD 10^6 led to similar results (fig. S8). To further generalize these results, we modified our mathematical formula to predict the impacts of per-individual test refusal and per-test sampling-related sensitivity on the reproductive number R (see text S1).

DISCUSSION

Our results lead us to conclude that repeated population screening of asymptomatic individuals can be used to limit the spread of SARS-CoV-2. However, our findings are subject to a number of limitations. First, the sensitivity of a test may depend on factors beyond LOD, including manufacturer variation and improper clinical sampling (33), although the latter may be ameliorated by different approaches to sample collection, such as saliva-based testing (34). Second, the exact performance differences between testing schemes will depend on whether our model truly captures viral kinetics and infectiousness profiles (21), particularly during the acceleration phase between exposure and peak viral load. Continued clarification of these within-host dynamics would increase the impact and value of this, and other (31, 32, 35, 36) modeling studies. Last, we modeled participation in screening regimens (or refusal thereof) as statistically independent between individuals, but health-related behaviors




Fig. 6. Repeated population screening suppresses an ongoing epidemic. Widespread testing and isolation of infected individuals drive prevalence downward for both (A) the fully mixed compartmental model and (B) the agent-based model. Time series of prevalence, measured as the total number of infectious individuals, are shown for no intervention (solid) and population screening scenarios (various dashed lines; see legend) for individual stochastic simulations. Screening began only when prevalence reached 4% (box), and time series are shifted such that testing begins at $t = 0$. Scenarios show the impact of a test with $LOD 10^5$, no delay in results, and with 10% of samples assumed to be incorrectly collected (and therefore negative) to reflect decreased sensitivity incurred at sample collection in a mass testing scenario. Annotations show total number of post-intervention infections, as a percentage of the no-intervention scenario, labeled as 100% (see fig. S8 for identical simulations using a test with $LOD 10^6$).




Fig. 7. Example asymptomatic and symptomatic viral loads with model control points. Examples of model viral loads (lines) and corresponding stochastically drawn control points (squares and circles) are shown for (A) an asymptomatic viral load trajectory and (B) a symptomatic viral load trajectory. Because simulations took place in discrete time, black dots show points at which this example viral load would have been sampled. Light gray lines show 20 alternative trajectories in each panel to illustrate the diversity of viral loads drawn from the simple model. Red circles indicate the control points that are modified in symptomatic trajectories to account for symptom onset and prolonged time until clearance.

have been shown to be socially (37) and geographically (38, 39) correlated. Clustered refusal of testing or refusal to isolate upon testing positive could present challenging barriers to implementation.

Our findings show that the impact of repeated population screening can be expressed as a reduction of the reproductive number R . By mapping a given testing regimen to a reduction in R , the impact of testing regimen can be approximated and generalized without complicated simulations. For instance, one could estimate the maximum allowable turnaround time delays or the minimum testing frequency required to bring R below one on the basis of user-specified and scenario-specific assumptions. To facilitate such generalizations and scenario planning, open-source calculation tools accompany this manuscript.

A critical point is that the requirements for screening tests are distinct from clinical tests. Clinical diagnoses target symptomatic individuals, need high accuracy and sensitivity, and are not limited by cost. Because they focus on symptomatic individuals, those individuals can isolate such that a diagnosis delay does not lead to additional infections. In contrast, results from the screening of asymptomatic individuals need to be returned quickly since even a single-day diagnosis delay compromises the screening program's effectiveness. At least for viruses with infection kinetics similar to SARS-CoV-2, we find that speed of reporting is much more important than sensitivity, although more sensitive tests are nevertheless somewhat more effective.

The difference between clinical and screening tests highlights the need for additional tests to be approved and used for screening. These tests should not be held to the same degree of sensitivity as clinical tests, particularly if doing so encumbers rapid deployment of faster cheaper SARS-CoV-2 assays. We suggest that the U.S. Food and Drug Administration, other agencies, or state governments encourage the development and use of alternative faster and lower-cost tests for public health and repeated population screening purposes, even if they have poorer LODs. If the availability of point-of-care or self-administered screening tests leads to faster turnaround time or more frequent testing, then our results suggest that they would have high epidemiological value.

Our modeling suggests that some types of repeated population screening will subject some individuals to unnecessary quarantine days. For instance, the infrequent use of a sensitive test will identify not only (i) those with a low viral load in the beginning of the infection, who must be isolated to limit viral spread, but also (ii) those in the recovery period, who still have detectable virus or RNA but are below the infectious threshold (13, 14). Isolating this second group of patients will have no impact on viral spread but will incur costs of isolation, as would the isolation of individuals who received a false-positive test result due to imperfect test specificity. The use of serology, repeat testing 24 or 48 hours apart, or some other test to distinguish low-viral load patients on the upslope of infection from those in the recovery phase could allow for more effective quarantine decisions.

MATERIALS AND METHODS

Viral loads

Viral loads were drawn from a simple viral kinetics model intended to capture (i) a variable latent period, (ii) a rapid growth phase from

the lower limit of PCR detectability to a peak viral load, (iii) a slower decay phase, and (iv) prolonged clearance for symptomatic infections versus asymptomatic infections. These dynamics were based on the following observations.

Latent periods before symptoms have been estimated to be around 5 days (40). Latent periods before detection via virological tests at secondary sites of replication or shedding have been estimated to be up to 4 days (41), corresponding to a latent or eclipse phase observed with other viruses (42). Viral load appears to peak before symptom onset (21) and peaks within 2 days of challenge in a macaque model (43, 44), although it should be noted that macaque challenge doses were high. Viral load decreases monotonically from the time of symptom onset (21, 45–48) but may be high and detectable 3 or more days before symptom onset (1, 49). Peak viral loads are difficult to measure because of lack of prospective sampling studies of individuals before exposure and infection, but viral loads have been reported in the range of $\mathcal{O}(10^4)$ to $\mathcal{O}(10^9)$ cp/ml (12, 47, 48). Viral loads appear to become undetectable by PCR within 3 weeks of symptom onset (45, 48, 50), but detectability and timing may differ, depending on the degree or presence of symptoms (50, 51). The majority of studies reviewed by Cevik *et al.* (18) found initial viral loads to be similar between symptomatic and asymptomatic infections (1, 24–26), but viral clearance was significantly and substantially faster among asymptomatic infections (24, 26–29). Last, we note that the general understanding of viral kinetics may vary depending on the mode of sampling, as demonstrated via a comparison between sputum and swab samples (12). For a comprehensive review of viral load dynamics, duration of shedding, and infectiousness, see (18).

To mimic growth and decay, \log_{10} viral loads were specified by a continuous piecewise linear “hinge” function, specified uniquely with three control points: $(t_0, 3)$, $(t_{\text{peak}}, V_{\text{peak}})$, $(t_f, 6)$ (Fig. 7A, green squares). The first point represents the time at which an individual’s viral load first crosses 10^3 , with $t_0 \sim \text{unif}[2.5, 3.5]$, measured in days since exposure. The second point represents the peak viral load. Peak height was drawn $V_{\text{peak}} \sim \text{unif}[7, 11]$, and peak timing was drawn with respect to the start of the exponential growth phase, $t_{\text{peak}} - t_0 \sim 0.5 + \text{gamma}(1.5)$ with a maximum of 3. The third point represents the time at which an individual’s viral load crosses beneath the 10^6 threshold, at which point viral loads no longer cause active cultures in laboratory experiments (11–13, 18). For asymptomatic infections, this point was drawn with respect to peak timing, $t_f - t_{\text{peak}} \sim \text{unif}[4, 9]$. For symptomatic infections, a symptom onset time was first drawn with respect to peak timing, $t_{\text{symptoms}} - t_{\text{peak}} \sim \text{unif}[0, 3]$, and then, the third control point was drawn with respect to symptom onset, $t_f - t_{\text{symptoms}} \sim \text{unif}[4, 9]$. Thus, symptomatic trajectories are systematically longer, in both duration of infectiousness (see below) and duration of viral shedding, reflecting the documented prolonged clearance and relationship with viral culture experiments (Fig. 7B, red circles). In simulations, each viral load’s parameters were drawn independently of others, and the continuous function described here was evaluated at 28 integer time points (Fig. 7, black dots) representing a 4-week span of viral load values.

Infectiousness

Infectiousness F was assumed to be directly related to viral load V in one of three ways. In the main text, each individual’s relative infectiousness was proportional \log_{10} of viral load’s excess beyond 10^6 , i.e., $F \propto \log_{10}(V) - 6$. In the supplementary sensitivity analyses, we

investigated two opposing extremes. To capture a more extreme relationship between infectiousness and viral load, we considered F to be directly proportional to viral load’s excess above 10^6 , i.e., $F \propto 10^{\log_{10}(V) - 6} = V \times 10^{-6}$, and to capture a more extreme relationship, but in the opposing direction, we considered F to simply be a constant when viral load exceeded 10^6 , i.e., $F \propto 1_{V > 10^6}$. We call these three functions log-proportional, proportional, and threshold throughout the text and the Supplementary Materials.

We note that a comprehensive review of viral loads, shedding, and infectiousness (18) found that, across the surveyed literature, no virus could be cultured beyond 9 days after symptoms. Thus, the choice of the final control point in our symptomatic viral load model (Fig. 7B), which corresponds to the latest time at which an individual is infectious, is, at most, 9 days after symptom onset.

Recently, He *et al.* (21) published an analysis of infectiousness relative to symptom onset that was corrected by Bonhoeffer *et al.* [see (21) for details]. Among our infectiousness functions, this inferred relationship bears the greatest similarity, over time, to the log-proportional infectiousness function, as visualized in Figs. 1 and 4. The proportional and threshold models therefore represent one of many types of sensitivity analysis. Results for those models can be found in figs. S2, S3, and S5. In all simulations, the value of the proportionality constant implied by the infectiousness functions above was chosen to achieve the targeted value of R_0 for that simulation and confirmed via simulation as described below.

Disease transmission models

Overview

Two models were used to simulate SARS-CoV-2 dynamics, both based on a typical compartmental framework. The first model was a fully mixed model of $N = 20,000$ individuals with all-to-all contact structure, zero initial infections, and a constant $1/N$ per-person probability of becoming infected from an external source. This model could represent, for instance, a large college campus with high mixing, situated within a larger community with low-level disease prevalence. The second model was an agent-based model of $N = 8.4$ million agents representing the population and contact structure of New York City, as previously described (30). Contact patterns were based on a combination of individual-level household contacts drawn from census microdata and age-stratified contact matrices, which describe outside of household contacts. This model was initialized with 100 initial infections and no external sources of infection.

Both the fully mixed and agent-based models tracked discrete individuals who were Susceptible (S), Infected (I), Recovered (R), Isolated (Q), and Self-Isolated (SQ) at each discrete 1-day time step. Upon becoming infected ($S \rightarrow I$), a viral load trajectory $V(t)$ was drawn, which included a latent period, growth, and decay. Each day, an individual’s viral load trajectory was used to determine whether their diagnostic test would be positive if administered, as well as their infectiousness to susceptible individuals. On the basis of a schedule of testing each person every D days, if an individual happened to be tested on a day when their viral load exceeded the LOD L of the test, then their positive result would cause them to isolate ($I \rightarrow Q$), but with the possibility of a delay in turnaround time. A fraction $1-f$ of individuals self-isolate on the day of symptom onset, which occurs 0 to 3 days after peak viral load, to mimic symptom-driven isolation ($I \rightarrow SQ$), with $f = 0.65$ for both models and with $f = 0.8$ and $f = 0.5$ explored in sensitivity analyses (fig. S4).

Presymptomatic individuals were isolated before symptom onset only if they received positive test results. When an individual's viral load dropped below 10^3 , that individual recovered ($I, Q, SQ \rightarrow R$). Details follow.

Testing, isolation, and sample-to-answer turnaround times

All individuals were tested every D days so that they could be moved into isolation if their viral load exceeded the test's LOD $V(t) > L$. Each person was deterministically tested exactly every D days, but testing days were drawn uniformly at random such that not all individuals were tested on the same day. To account for delays in returning test results, we included a sample-to-answer turnaround time T , meaning that an individual with a positive test on day t would isolate on day $t + T$.

Transmission, population structure, and mixing patterns: Fully mixed model

Simulations were initialized with all individuals susceptible, $S = N$. Each individual was chosen to be symptomatic independently with probability f , and each individual's first test day (e.g., the day of the week that their weekly test would occur) was chosen uniformly at random between 1 and D . Relative infectiousness was scaled up or down to achieve the specified R_0 in the absence of any testing policy but inclusive of any assumed self-isolation of symptomatics.

In each time step, those individuals who were marked for testing that day were tested, and a counter was initialized to T , specifying the number of days until that individual received their results. Next, individuals whose test result counters were zero were isolated, $I \rightarrow Q$. Then, symptomatic individuals whose viral load had declined relative to the previous day were self-isolated, $I \rightarrow SQ$. Next, each susceptible individual was spontaneously (externally) infected independently with probability $1/N$, $S \rightarrow I$. Then, all infected individuals contacted all susceptible individuals, with the probability of transmission based on that day's viral load $V(t)$ for each person and the particular infectiousness function, described above, $S \rightarrow I$. To conclude each time step, individuals' viral loads and test result counters were advanced, with those whose infectious period had completely passed moved to recovery, $I, Q, SQ \rightarrow R$.

Transmission, population structure, and mixing patterns: Agent-based model

The agent-based model added viral kinetics and testing policies (as described above) to an existing model for SARS-CoV-2 transmission in New York City. A full description of the agent-based model is available (30); here, we provide an overview of the relevant transmission dynamics.

Simulations were initialized with all individuals susceptible, except for 100 initially infected individuals, $S = N - 100$. As in the fully mixed model, each individual's test day was chosen uniformly at random and relative infectiousness was scaled to achieve the specified R_0 .

In each time step, those individuals who were marked for testing that day were tested, and a counter was initialized to T , specifying the number of days until that individual received their results. Next, individuals whose test result counters were zero were isolated, $I \rightarrow Q$. There was no self-isolation in this model (and accordingly, the model did not label individuals as symptomatic or asymptomatic).

Then, transmission from infected individuals to susceptible individuals was simulated both within and outside households. To model within-household transmission, each individual had a set of other individuals comprising their household. Household structures, along with the age of each individual, were sampled from cen-

sus microdata for New York City (52). The probability for an infectious individual to infect each of their household members each day was determined by scaling the relative infectiousness values to match the estimated secondary attack rate for close household contacts previously reported in case cluster studies (53).

Outside of household transmission was simulated using age-stratified contact matrices, which describe the expected number of daily contacts between an individual in a given age group and those in each other age group. Each infectious individual of age i drew Poisson(M_{ij}) contacts with individuals in age group j , where M is the contact matrix. The contacted individuals were sampled uniformly at random from age group j . We use a contact matrix for the United States estimated in (54). Each contact resulted in infection, $S \rightarrow I$, with probability proportional to the relative infectiousness of the infected individual on that day, scaled to obtain the specified value of R_0 . To conclude each time step, individuals' viral loads and test results counters were advanced, with those whose infectious period had completely passed moved to recovery, $I, Q \rightarrow R$.

Calibration to achieve targeted R_0 and estimation of R

As a consistency check, each simulation's R_0 was estimated as follows to ensure that simulations were properly calibrated to their intended values. Note that to vary R_0 , the proportionality constant in the function that maps viral load to infectiousness need only be adjusted up or down. In a typical Susceptible Exposed Infected Recovered (SEIR) model, this would correspond to changing the infectiousness parameter, which governs the rate at which I -to- S contacts cause new infections β .

For the fully mixed, the value of R_0 was numerically estimated by running single-generation simulations in which 50 infected individuals were placed in a population of $N - 50$ others. The number of secondary infections from those initially infected was recorded and used to directly estimate R_0 .

For the agent-based model, the value of R_0 depends on the distribution of infected agents due to stratification by age and household. We numerically estimate R_0 by averaging over the number of secondary infections caused by each agent who was infected in the first 15 days of the simulation (at which point, the population is still more than 99.99% susceptible).

Estimations of R proceeded exactly as estimations of R_0 for both models, except with interventions applied to the viral loads and, therefore, the dynamics. Prediction of R without direct simulation is described in text S1.

SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at <http://advances.sciencemag.org/cgi/content/full/sciadv.abd5393/DC1>

[View/request a protocol for this paper from Bio-protocol.](#)

REFERENCES AND NOTES

1. M. M. Arons, K. M. Hatfield, S. C. Reddy, A. Kimball, A. James, J. R. Jacobs, J. Taylor, K. Spicer, A. C. Bardossy, L. P. Oakley, S. Tanwar, J. W. Dyal, J. Harney, Z. Chisty, J. M. Bell, M. Methner, P. Paul, C. M. Carlson, H. P. McLaughlin, N. Thornburg, S. Tong, A. Tamin, Y. Tao, A. Uehara, J. Harcourt, S. Clark, C. Brostrom-Smith, L. C. Page, M. Kay, J. Lewis, P. Montgomery, N. D. Stone, T. A. Clark, M. A. Honein, J. S. Duchin, J. A. Jernigan; Public Health—Seattle and King County; CDC COVID-19 Investigation Team, Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. *N. Engl. J. Med.* **382**, 2081–2090 (2020).
2. D. Sutton, K. Fuchs, M. D'Alton, D. Goffman, Universal screening for SARS-CoV-2 in women admitted for delivery. *N. Engl. J. Med.* **382**, 2163–2164 (2020).
3. D. P. Oran, E. J. Topol, Prevalence of asymptomatic SARS-CoV-2 infection: A narrative review. *Ann. Intern. Med.* **173**, 362–367 (2020).

4. S. M. Moghadas, M. C. Fitzpatrick, P. Sah, A. Pandey, A. Shoukat, B. H. Singer, A. P. Galvani, The implications of silent transmission for the control of COVID-19 outbreaks. *Proc. Natl. Acad. Sci. U.S.A.* **117**, 17513–17515 (2020).
5. N. C. Grassly, M. Pons-Salort, E. P. K. Parker, P. J. White, N. M. Ferguson; Imperial College COVID-19 Response Team, Comparison of molecular testing strategies for COVID-19 control: A mathematical modelling study. *Lancet Infect. Dis.*, S1473-3099(20)30630-7 (2020).
6. C. B. F. Vogels, A. F. Brito, A. L. Wyllie, J. R. Fauver, I. M. Ott, C. C. Kalinich, M. E. Petrone, M. L. Landry, E. F. Foxman, N. D. Grubaugh, Analytical sensitivity and efficiency comparisons of SARS-CoV-2 qRT-PCR assays. *medRxiv* 10.1101/2020.03.30.20048108, (2020).
7. D. J. Butler, C. Mozsary, C. Meydan, D. Danko, J. Foox, J. Rosiene, A. Shaiber, E. Afshinnekoo, M. M. Kay, F. J. Sedlaczek, N. A. Ivanov, M. Sierra, D. Pohle, M. Zietz, U. Gisladdottir, V. Ramlall, C. D. Westover, K. Ryon, B. Young, C. Bhattacharya, P. Ruggiero, B. W. Langhorst, N. Tanner, J. Gawry, D. Meleshko, D. Xu, P. A. D. Steel, A. J. Shemesh, J. Xiang, J. Thierry-Mieg, D. Thierry-Mieg, R. E. Schwartz, A. Iftner, D. Bezdán, J. Siple, L. Cong, A. Craney, P. Velu, A. M. Melnick, I. Hajirasouliha, S. M. Horner, T. Iftner, M. Salvatore, M. Loda, L. F. Westblade, M. Cushing, S. Levy, S. Wu, N. Tatonetti, M. Imlinski, H. Rennert, C. E. Mason, Shotgun transcriptome and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. *bioRxiv* 2020.04.20.048066 [Preprint] (2020).
8. V. L. D. Thi, K. Herbst, K. Boerner, M. Meurer, L. P. M. Kremer, D. Kirmaier, A. Freistaedter, D. Papagiannidis, C. Galmozzi, M. L. Stanifer, S. Boulant, S. Klein, P. Chlanda, D. Khalid, I. B. Miranda, P. Schnitzler, H.-G. Kräusslich, M. Knop, S. Anders, A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples. *Sci. Transl. Med.* **12**, eabc7075 (2020).
9. N. R. Meyerson, Q. Yang, S. K. Clark, C. L. Paige, W. T. Fattor, A. R. Gilchrist, A. Barbachano-Guerrero, S. L. Sawyer, A community-deployable SARS-CoV-2 screening test using raw saliva with 45 minutes sample-to-results turnaround. *medRxiv* 2020.07.16.20150250, (2020).
10. Coronavirus (COVID-19) update: FDA informs public about possible accuracy concerns with Abbott ID NOW Point-of-Care Test (2020); <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-informs-public-about-possible-accuracy-concerns-abbott-id-now-point>.
11. E. N. Gallichotte, K. M. Quicke, N. R. Sexton, E. Fitzmeyer, M. C. Young, A. J. Janich, K. Dobos, K. L. Pablonia, G. Gahm, E. J. Carlton, G. D. Ebel, N. Ehrhart, Longitudinal surveillance for SARS-CoV-2 RNA among asymptomatic staff in five colorado skilled nursing facilities: Epidemiologic, virologic and sequence analysis. *medRxiv* 2020.06.08.20125989, (2020).
12. R. Wölfel, V. M. Corman, W. Guggemos, M. Seilmaier, S. Zange, M. A. Müller, D. Niemeyer, T. C. Jones, P. Vollmar, C. Rothe, M. Hoelscher, T. Bleicker, S. Brünink, J. Schneider, R. Ehmann, K. Zwirgmaier, C. Drosten, C. Wendtner, Virological assessment of hospitalized patients with COVID-2019. *Nature* **581**, 465–469 (2020).
13. B. La Scola, M. L. Bideau, J. Andreani, V. T. Hoang, C. Grimaldier, P. Colson, P. Gautret, D. Raoult, Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. *Eur. J. Clin. Microbiol. Infect. Dis.* **39**, 1059–1061 (2020).
14. S. Alexandersen, A. Chamings, T. R. Bhatta, SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication. *medRxiv* 2020.06.01.20119750, (2020).
15. C. G. B. Caraguel, H. Stryhn, N. Gagné, I. R. Dohoo, K. L. Hammell, Selection of a cutoff value for real-time polymerase chain reaction results to fit a diagnostic purpose: Analytical and epidemiologic approaches. *J. Vet. Diagn. Invest.* **23**, 2–15 (2011).
16. A. Ruiz-Villalba, E. van Pelt-Verkuil, Q. D. Gunst, J. M. Ruijter, M. J. van den Hoff, Amplification of nonspecific products in quantitative polymerase chain reactions (qPCR). *Biomol. Detect. Quantif.* **14**, 7–18 (2017).
17. P. J. Klasse, Molecular determinants of the ratio of inert to infectious virus particles, in *Progress in Molecular Biology and Translational Science* (Elsevier, 2015), vol. 129, pp. 285–326.
18. M. Cevik, M. Tate, O. Lloyd, A. E. Maraolo, J. Schafers, A. Ho, SARS-CoV-2, SARS-CoV-1 and MERS-CoV viral load dynamics, duration of viral shedding and infectiousness: A living systematic review and meta-analysis. *medRxiv* 2020.07.25.20162107, (2020).
19. A. M. Smith, A. S. Perelson, Influenza A virus infection kinetics: Quantitative data and models. *Wiley Interdiscip. Rev. Syst. Biol. Med.* **3**, 429–445 (2011).
20. M. Richard, A. Kok, D. de Meulder, T. M. Bestebroer, M. M. Lamers, N. M. A. Okba, M. F. van Vliening, B. Rockx, B. L. Haagmans, M. P. G. Koopmans, R. A. M. Fouchier, S. Herfst, SARS-CoV-2 is transmitted via contact and via the air between ferrets. *bioRxiv* 2020.04.16.044503 [Preprint] (2020).
21. X. He, E. H. Y. Lau, P. Wu, X. Deng, J. Wang, X. Hao, Y. C. Lau, J. Y. Wong, Y. Guan, X. Tan, X. Mo, Y. Chen, B. Liao, W. Chen, F. Hu, Q. Zhang, M. Zhong, Y. Wu, L. Zhao, F. Zhang, B. J. Cowling, F. Li, G. M. Leung, Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat. Med.* **26**, 672–675 (2020).
22. Z. Shen, F. Ning, W. Zhou, X. He, C. Lin, D. P. Chin, Z. Zhu, A. Schuchat, Superspreading SARS events, Beijing, 2003. *Emerg. Infect. Dis.* **10**, 256 (2004).
23. J. S. M. Peiris, C. M. Chu, V. C. C. Cheng, K. S. Chan, I. F. N. Hung, L. L. M. Poon, K. I. Law, B. S. F. Tang, T. Y. W. Hon, C. S. Chan, K. H. Chan, J. S. C. Ng, B. J. Zheng, W. L. Ng, R. W. M. Lai, Y. Guan, K. Y. Yuen; HKU/UCH SARS Study Group, Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. *Lancet* **361**, 1767–1772 (2003).
24. Z. Zhang, T. Xiao, Y. Wang, J. Yuan, H. Ye, L. Wei, H. Wang, X. Liao, S. Qian, Z. Wang, L. Liu, Early viral clearance and antibody kinetics of COVID-19 among asymptomatic carriers. *medRxiv* 2020.04.28.20083139, (2020).
25. E. Lavezzo, E. Franchin, C. Ciavarella, G. Cuomo-Dannenburg, L. Barzon, C. D. Vecchio, L. Rossi, R. Manganelli, A. Lorigian, N. Navarin, D. Abate, M. Sciro, S. Merigliano, E. De Canale, M. C. Vanuzzo, V. Besutti, F. Saluzzo, F. Onelia, M. Pacenti, S. G. Parisi, G. Carretta, D. Donato, L. Flor, S. Cocchio, G. Masi, A. Sperduti, L. Cattarino, R. Salvador, M. Nicoletti, F. Caldari, G. Castellini, E. Nieddu, B. Labella, L. Fava, M. Drigo, K. A. M. Gaythorpe; Imperial College COVID- Response Team, A. R. Brazzale, S. Toppo, M. Trevisan, V. Baldo, C. A. Donnelly, N. M. Ferguson, I. Dorigatti, A. Crisanti, Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature*, 425–429 (2020).
26. N. V. V. Chau, V. T. Lam, N. T. Dung, L. M. Yen, N. N. Q. Minh, L. M. Hung, N. M. Ngoc, N. T. Dung, D. N. H. Man, L. A. Nguyet, L. T. H. Nhat, L. N. T. Nhu, N. T. H. Ny, N. T. T. Hong, E. Kestelyn, N. T. P. Dung, N. T. Phong, T. C. Xuan, T. T. Hien, T. N. H. Tu, R. B. Geskus, T. T. Thanh, N. T. Truong, N. T. Binh, T. C. Thuong, G. Thwaites, L. Van Tan, The natural history and transmission potential of asymptomatic SARS-CoV-2 infection. *medRxiv* 2020.04.27.20082347, (2020).
27. X. Chen, Y. Zhang, B. Zhu, J. Zeng, W. Hong, X. He, J. Chen, H. Zheng, S. Qiu, Y. Deng, J. Chan, J. Wang, Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: A retrospective cohort study. *medRxiv* 2020.04.09.20058941, (2020).
28. Z. Hu, C. Song, C. Xu, G. Jin, Y. Chen, X. Xu, H. Ma, W. Chen, Y. Lin, Y. Zheng, J. Wang, Z. Hu, Y. Yi, H. Shen, Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Sci. China Life Sci.* **63**, 706–711 (2020).
29. R. Yang, X. Gui, Y. Xiong, Comparison of clinical characteristics of patients with asymptomatic vs symptomatic coronavirus disease 2019 in Wuhan, China. *JAMA Netw. Open* **3**, e2010182 (2020).
30. B. Wilder, M. Charpignon, J. A. Killian, H.-C. Ou, A. Mate, S. Jabbari, A. Perrault, A. N. Desai, M. Tambe, M. S. Majumder, Modeling between-population variation in COVID-19 dynamics in Hubei, Lombardy, and New York City. *Proc. Natl. Acad. Sci. U.S.A.* **117**, 25904–25910 (2020).
31. C. M. Peak, R. Kahn, Y. H. Grad, L. M. Childs, R. Li, M. Lipsitch, C. O. Buckee, Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: A modelling study. *Lancet Infect. Dis.* **20**, 1025–1033 (2020).
32. A. J. Kucharski, P. Klepac, A. Conlan, S. M. Kissler, M. Tang, H. Fry, J. Gog, J. Edmunds; CMMID COVID-19 Working Group, Effectiveness of isolation, testing, contact tracing and physical distancing on reducing transmission of SARS-CoV-2 in different settings. *medRxiv* 2020.04.23.20077024, (2020).
33. Y. Fang, H. Zhang, J. Xie, M. Lin, L. Ying, P. Pang, W. Ji, Sensitivity of chest CT for COVID-19: Comparison to RT-PCR. *Radiology* **296**, E115–E117 (2020).
34. A. L. Wyllie, J. Fournier, A. Casanovas-Massana, M. Campbell, M. Tokuyama, P. Vijayakumar, B. Geng, M. C. Muenker, A. J. Moore, C. B. F. Vogels, M. E. Petrone, I. M. Ott, P. Lu, A. Lu-Culligan, J. Klein, A. Venkataraman, R. Earnest, M. Simonov, R. Datta, R. Handoko, N. Naushad, L. R. Sewanan, J. Valdez, E. B. White, S. Lapidus, C. C. Kalinich, X. Jiang, D. J. Kim, E. Kudo, M. Linehan, T. Mao, M. Moriyama, J. E. Oh, A. Park, J. Silva, E. Song, T. Takahashi, M. Taura, O.-E. Weizman, P. Wong, Y. Yang, S. Bermejo, C. Odio, S. B. Omer, C. S. Dela Cruz, S. Farhadian, R. A. Martinello, A. Iwasaki, N. D. Grubaugh, A. I. Ko, Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. *medRxiv* 2020.04.16.20067835, (2020).
35. E. T. Chin, B. Q. Huynh, L. A. C. Chapman, M. Murrill, S. Basu, N. C. Lo, Frequency of routine testing for COVID-19 in high-risk environments to reduce workplace outbreaks. *medRxiv* 2020.04.30.20087015, (2020).
36. A. D. Paltiel, A. Zheng, R. P. Walensky, Assessment of SARS-CoV-2 screening strategies to permit the safe reopening of college campuses in the United States. *JAMA Netw. Open* **3**, e2016818 (2020).
37. D. Holtz, M. Zhao, S. G. Benzell, C. Y. Cao, M. A. Rahimian, J. Yang, J. Allen, A. Collis, A. Moehring, T. Sowrirajan, D. Ghosh, Y. Zhang, P. S. Dhillon, C. Nicolaides, D. Eckles, S. Aral, Interdependence and the cost of uncoordinated responses to COVID-19. *Proc. Natl. Acad. Sci. U.S.A.* **117**, 19837–19843 (2020).
38. T. A. Lieu, G. T. Ray, N. P. Klein, C. Chung, M. Kulldorff, Geographic clusters in underimmunization and vaccine refusal. *Pediatrics* **135**, 280–289 (2015).
39. S. M. Kissler, N. Kishore, M. Prabhu, D. Goffman, Y. Beilin, R. Landau, C. Gyamfi-Bannerman, B. T. Bateman, J. Snyder, A. S. Razavi, D. Katz, J. Gal, A. Bianco, J. Stone, D. Larremore, C. O. Buckee, Y. H. Grad, Reductions in commuting mobility correlate with geographic differences in SARS-CoV-2 prevalence in New York City. *Nat. Commun.* **11**, 4674 (2020).

40. S. A. Lauer, K. H. Grantz, Q. Bi, F. K. Jones, Q. Zheng, H. R. Meredith, A. S. Azman, N. G. Reich, J. Lessler, The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation and application. *Ann. Intern. Med.* **172**, 577–582 (2020).
41. E. A. H. Vargas, J. X. Velasco-Hernandez, In-host modelling of COVID-19 kinetics in humans. *medRxiv* 2020.03.26.20044487, (2020).
42. J. M. Burke, C. R. Bass, R. P. Kincaid, E. T. Ulug, C. S. Sullivan, The murine polyomavirus microRNA locus is required to promote viruria during the acute phase of infection. *J. Virol.* **92**, e02131–17 (2018).
43. A. Chandrashekar, J. Liu, A. J. Martinot, K. M. Mahan, N. B. Mercado, L. Peter, L. H. Tostanoski, J. Yu, Z. Maliga, M. Nekorchuk, K. Busman-Sahay, M. Terry, L. M. Wrijil, S. Ducat, D. R. Martinez, C. Atyeo, S. Fischinger, J. S. Burke, M. D. Slein, L. Pessaint, A. Van Ry, J. Greenhouse, T. Taylor, K. Blade, A. Cook, B. Finneyfrock, R. Brown, E. Teow, J. Velasco, R. Zahn, F. Wegmann, P. Abbink, E. A. Bondzie, G. Dagotto, M. S. Gebre, X. He, C. Jacob-Dolan, N. Kordana, Z. Li, M. A. Lifton, S. H. Mahrokhian, L. F. Maxfield, R. Nityanandam, J. P. Nkolola, A. G. Schmidt, A. D. Miller, R. S. Baric, G. Alter, P. K. Sorger, J. D. Estes, H. Andersen, M. G. Lewis, D. H. Barouch, SARS-CoV-2 infection protects against rechallenge in rhesus macaques. *Science* **369**, 812–817 (2020).
44. J. Yu, L. H. Tostanoski, L. Peter, N. B. Mercado, K. M. Mahan, S. H. Mahrokhian, J. P. Nkolola, J. Liu, Z. Li, A. Chandrashekar, D. R. Martinez, C. Loos, C. Atyeo, S. Fischinger, J. S. Burke, M. D. Slein, Y. Chen, A. Zuiani, F. J. N. Lelis, M. Travers, S. Habibi, L. Pessaint, A. Van Ry, K. Blade, R. Brown, A. Cook, B. Finneyfrock, A. Dodson, E. Teow, J. Velasco, R. Zahn, F. Wegmann, E. A. Bondzie, G. Dagotto, M. S. Gebre, X. He, C. Jacob-Dolan, M. Kirilova, N. Kordana, Z. Lin, L. F. Maxfield, F. Nampanya, R. Nityanandam, J. D. Ventura, H. Wan, Y. Cai, B. Chen, A. G. Schmidt, D. R. Wesemann, R. S. Baric, G. Alter, H. Andersen, M. G. Lewis, D. H. Barouch, DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science* **369**, 806–811 (2020).
45. B. Borremans, A. Gamble, K. C. Prager, S. K. Helman, A. M. McClain, C. Cox, V. Savage, J. O. Lloyd-Smith, Quantifying antibody kinetics and RNA shedding during early-phase SARS-CoV-2 infection. *medRxiv* 2020.05.15.20103275, (2020).
46. J. J. A. van Kampen, D. A. M. C. van de Vijver, P. L. A. Fraaij, B. L. Haagmans, M. M. Lamers, N. Okba, J. P. C. van den Akker, H. Endeman, D. A. M. P. J. Gommers, J. J. Cornelissen, R. A. S. Hoek, M. M. van der Eerden, D. A. Hesselink, H. J. Metselaar, A. Verbon, J. E. M. de Steenwinkel, G. I. Aron, E. C. M. van Gorp, S. van Boheemen, J. C. Voermans, C. A. B. Boucher, R. Molenkamp, M. P. G. Koopmans, C. Geurtsvankessel, A. A. van der Eijk, Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): Duration and key determinants. *medRxiv* 2020.06.08.20125310, (2020).
47. H. Kawasuji, Y. Takegoshi, M. Kaneda, A. Ueno, Y. Miyajima, K. Kawago, Y. Fukui, Y. Yoshida, M. Kimura, H. Yamada, I. Sakamaki, H. Tani, Y. Morinaga, Y. Yamamoto, Viral load dynamics in transmissible symptomatic patients with COVID-19. *medRxiv* 2020.06.02.20120014, (2020).
48. K. K.-W. To, O. T.-Y. Tsang, W.-S. Leung, A. R. Tam, T.-C. Wu, D. C. Lung, C. C.-Y. Yip, J.-P. Cai, J. M.-C. Chan, T. S.-H. Chik, D. P.-L. Lau, C. Y.-C. Choi, L.-L. Chen, W.-M. Chan, K.-H. Chan, J. D. Ip, A. C.-K. Ng, R. W.-S. Poon, C.-T. Luo, V. C.-C. Cheng, J. F.-W. Chan, I. F.-N. Hung, Z. Chen, H. Chen, K.-Y. Yuen, Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: An observational cohort study. *Lancet Infect. Dis.* **20**, 565–574 (2020).
49. J. Y. Kim, J. H. Ko, Y. Kim, Y. J. Kim, J. M. Kim, Y. S. Chung, H. M. Kim, M. G. Han, S. Y. Kim, B. S. Chin, Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea. *J. Korean Med. Sci.* **35**, e86 (2019).
50. A. T. Xiao, Y. X. Tong, S. Zhang, Profile of RT-PCR for SARS-CoV-2: A preliminary study from 56 COVID-19 patients. *Clin. Infect. Dis.*, ciaa460 (2020).
51. Y. Liu, L.-M. Yan, L. Wan, T.-X. Xiang, A. Le, J.-M. Liu, M. Peiris, L. L. M. Poon, W. Zhang, Viral dynamics in mild and severe cases of COVID-19. *Lancet Infect. Dis.* **20**, 656–657 (2020).
52. Minnesota Population Center. Integrated public use microdata series, international: Version 7.2 [dataset] (IPUMS, 2019); <https://doi.org/10.18128/D020.V7.2>.
53. Y. Liu, R. Eggo, A. Kucharski, Secondary attack rate and superspreading events for SARS-CoV-2. *Lancet* **395**, e47 (2020).
54. K. Prem, A. Cook, M. Jit, Projecting social contact matrices in 152 countries using contact surveys and demographic data. *PLOS Comput. Biol.* **13**, e1005697 (2017).

Acknowledgments: We thank the BioFrontiers Institute IT HPC group. This work was supported by grants NIH F32 AI145112 (J.M.B.), NIH F30 AG063468 (E.L.), MURI W911NF1810208 (B.W. and M.T.), an NIH directors DP5 award 1DP5OD028145-01 (M.J.M.), and the Howard Hughes Medical Institute (R.P.). **Author contributions:** D.B.L., M.J.M., and R.P. conceived and designed the study. D.B.L., E.L., S.S., J.M.B., J.A.H., M.J.M., and R.P. developed the viral load model. D.B.L., B.W., and M.T. developed the epidemiological models. D.B.L. and B.W. conducted the simulations. D.B.L., M.J.M., and R.P. analyzed the data. All authors wrote and edited the manuscript. **Competing interests:** D.B.L. is a member of the scientific advisory board of Darwin Biosciences. The authors declare that they have no other competing interests. **Data and materials availability:** All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Open-source code is available at https://github.com/LarremoreLab/covid_testing. Additional data related to this paper may be requested from the authors.

Submitted 26 June 2020
Accepted 28 October 2020
First Release 20 November 2020
Published 1 January 2021
10.1126/sciadv.abd5393

Citation: D. B. Larremore, B. Wilder, E. Lester, S. Shehata, J. M. Burke, J. A. Hay, M. Tambe, M. J. Mina, R. Parker, Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. *Sci. Adv.* **7**, eabd5393 (2021).

Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening

Daniel B. Larremore, Bryan Wilder, Evan Lester, Soraya Shehata, James M. Burke, James A. Hay, Milind Tambe, Michael J. Mina and Roy Parker

Sci Adv 7 (1), eabd5393.

DOI: 10.1126/sciadv.abd5393originally published online November 20, 2020

ARTICLE TOOLS

<http://advances.sciencemag.org/content/7/1/eabd5393>

SUPPLEMENTARY MATERIALS

<http://advances.sciencemag.org/content/suppl/2020/11/20/sciadv.abd5393.DC1>

REFERENCES

This article cites 31 articles, 7 of which you can access for free
<http://advances.sciencemag.org/content/7/1/eabd5393#BIBL>

PERMISSIONS

<http://www.sciencemag.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of Service](#)

Science Advances (ISSN 2375-2548) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science Advances* is a registered trademark of AAAS.

Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).